GOG-3101 | TroFuse-20 Clinical Trial Update

In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer.

★ Support this podcast ★

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(16)

Accrual Culture: Top Points for Site Selection - Timelines

The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG GYN-LIVE Podcast:Corcept Therapeutics, GSK, Pfizer Oncology, Eli Lilly, Genmab, and Verastem ★ Su...

2 Apr 20min

Accrual Culture: Top Points for Site Selection - Responsiveness

6 Mar 17min

The GOG Highlight Reel - January 2026

The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major me...

20 Feb 2h 15min

KEYNOTE-B96 FDA APPROVAL REVIEW

16 Feb 19min

Accrual Culture: Top Points for Site Selection - Feasibility

5 Feb 15min

Accrual Culture: Top Points for Site Selection - Enrollement

The GOG Partners Leadership presents the “Accrual Culture: An Education Series on How to Build a Successful Clinical Trial Network.” The purpose of this on-demand education series is to share key comp...

30 Jan 18min